RxDoctor Payments Data

Gisela Vargas, MD

Family Medicine · Brandon, FLNPI 1073506267

Payments from drug & device makers

$4,557in general payments, 2019–2025

Across 187 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$619
  • Novo Nordisk$581
  • Lilly USA, LLC$546
  • Pfizer$379
  • Amgen$259
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,52799%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,557 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$17,552
Medicare patients
97
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$75,424
EliquisApixaban60$66,062
JanuviaSitagliptin Phosphate65$63,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$52,876
TrulicityDulaglutide44$52,156
LinzessLinaclotide53$47,825
JardianceEmpagliflozin25$35,199
OzempicSemaglutide23$32,868
MounjaroTirzepatide11$17,311
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,605
Albuterol Sulfate HfaAlbuterol Sulfate239$10,237
BelsomraSuvorexant23$9,701
Breo ElliptaFluticasone/Vilanterol11$9,132
XareltoRivaroxaban12$9,058
SymbicortBudesonide/Formoterol Fumarate22$6,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$619$94,317124 claims
MerckJanuvia, Belsomra$79$72,86988 claims
Lilly USA, LLCTrulicity, Mounjaro$546$69,46755 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,105$67,09989 claims
PfizerEliquis$379$66,06260 claims
AbbVieLinzess$118$47,82553 claims
Boehringer IngelheimJardiance$60$35,19925 claims
Novo NordiskOzempic$581$32,86823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →